Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma

Treatment for endometrial cancer is rapidly evolving with the increased use and integration of somatic tumor RNA sequencing in clinical practice. There is a paucity of data regarding PARP inhibition in endometrial cancer given that mutations in homologous recombination genes are rare, and currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Senguttuvan, Rosemary Noel, Wei, Christina, Raoof, Mustafa, Dellinger, Thanh H., Wang, Edward Wenge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253277/
https://www.ncbi.nlm.nih.gov/pubmed/37298034
http://dx.doi.org/10.3390/jcm12113839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253277/
https://www.ncbi.nlm.nih.gov/pubmed/37298034
http://dx.doi.org/10.3390/jcm12113839

Ejemplares similares